# Prolotherapy

Rating: Promising — Some human trials, or consistent animal work with a clear mechanism
Type: Therapy
Updated: 2026-10-15
Canonical: https://heretic.bio/articles/prolotherapy.html

> Prolotherapy injects a mild irritant, usually hyperosmolar dextrose, into ligament and tendon insertions to trigger controlled inflammation and new collagen growth. It is one of the better-evidenced regenerative injections: a systematic review found moderate evidence for safety and symptom control in knee osteoarthritis, with positive trials in tendinopathy and sacroiliac dysfunction. Serious adverse events are essentially absent from the literature. Caveats: it is rarely covered by insurance, and the evidence is still small trials rather than large definitive ones.

> **Core thesis:** Prolotherapy (proliferative therapy) is a regenerative injection technique that introduces a mild irritant solution — typically dextrose — into painful ligament, tendon, or joint sites. This triggers a controlled inflammatory healing response, stimulating new tissue growth and strengthening weakened connective tissue. It is one of the oldest, safest, and most evidence-supported regenerative techniques.

* * *

## Mechanism of Action

### The Healing Cascade Reactivation

  1. **Injection** of hyperosmolar dextrose (typically 12.5-25%) into ligament/tendon insertion or joint
  2. **Local osmotic shock** → controlled inflammation
  3. **Chemotaxis:** Neutrophils, macrophages, and fibroblasts recruited to the area
  4. **Fibroblast activation** → new collagen deposition
  5. **Neovascularization** → improved blood supply to poorly vascularized tissue
  6. **Tissue strengthening** over 4-8 weeks as new collagen matures and cross-links



### Why It Works: The Problem with Connective Tissue

  * Ligaments and tendons have **poor blood supply** — they don't heal well on their own
  * After injury, initial healing often produces **weak, disorganized scar tissue**
  * This weak tissue leads to **joint instability** → chronic pain, muscle spasm, and degeneration
  * Prolotherapy restarts the healing cascade to produce **stronger, organized collagen**



### The "Loose Ligament" Theory

  * Originated by George Hackett, MD (1950s): Weak or lax ligaments cause joint instability
  * Instability → chronic muscle spasm → referred pain patterns
  * By strengthening ligaments, prolotherapy addresses the root cause rather than masking pain



* * *

## Types of Prolotherapy

### Dextrose Prolotherapy (Standard)

  * **Solution:** 12.5-25% dextrose in local anesthetic
  * **Most common and best-studied** form
  * Safe, inexpensive, widely available



### Cellular Prolotherapy

  * Adds **PRP** or **stem cells** to the dextrose solution
  * Combines the proliferative stimulus with biological growth factors
  * More expensive but potentially more effective for advanced degeneration



### Neural Prolotherapy (Perineural Injection Treatment / PIT)

  * Developed by John Lyftogt, MD
  * **Solution:** 5% dextrose injected subcutaneously near superficial nerves
  * Targets **neurogenic inflammation** — TRPV1 receptor-mediated pain
  * Particularly effective for nerve-related pain (neuropathy, complex regional pain syndrome)



### Hackett-Hemwall Prolotherapy

  * Classical technique: multiple injection points along ligament/tendon insertions
  * Typically 3-6 treatment sessions at 4-6 week intervals
  * Named after pioneers George Hackett and Gustav Hemwall



* * *

## Clinical Evidence

### Knee Osteoarthritis (Strong Evidence)

  * **PMID[28334196](https://pubmed.ncbi.nlm.nih.gov/28334196/):** Systematic review found "moderate evidence that prolotherapy is safe and can help achieve significant symptomatic control in OA"
  * Multiple RCTs show improvement in pain, function, and range of motion
  * Compared favorably to exercise therapy, NSAIDs, and cortisone injections
  * Benefits sustained at 12-month follow-up in some studies



### Tendinopathy (Moderate-Strong)

  * **Achilles tendinopathy:** Significant improvement in pain and function
  * **Lateral epicondylitis (tennis elbow):** Multiple positive trials
  * **Rotator cuff tendinopathy:** Growing evidence of efficacy



### Low Back Pain (Moderate)

  * **Sacroiliac joint dysfunction:** Strong evidence for prolotherapy efficacy
  * **Ligamentous low back pain:** Multiple studies show benefit
  * Particularly effective when instability/laxity is the underlying issue



### Other Conditions

  * **TMJ disorders:** Case series and small trials show benefit
  * **Neck pain/whiplash:** Emerging evidence
  * **Joint hypermobility/Ehlers-Danlos:** Anecdotal but promising
  * **Plantar fasciitis:** Moderate evidence



* * *

## Uses

### What to Expect

  1. **24-72 hours post:** Temporary increase in soreness/stiffness (the inflammatory response)
  2. **Weeks 1-3:** Gradual improvement as new tissue forms
  3. **By week 4-6:** Significant improvement typically apparent
  4. **Cumulative:** Each session builds on previous tissue strengthening



### Adjunctive Measures

  * **Avoid NSAIDs** for 2-4 weeks post-treatment (NSAIDs suppress the intended inflammatory response)
  * **Gentle movement** encouraged (walking, ROM exercises)
  * **Avoid aggressive stretching** of treated areas for 2-3 weeks
  * **Physical therapy** often combined for optimal results



* * *

## Safety Profile

Aspect | Assessment  
---|---  
**Serious adverse events** | Extremely rare — no deaths or permanent injuries reported in literature  
**Common side effects** | Temporary soreness, bruising, stiffness (2-5 days)  
**Allergic reactions** | Rare — dextrose is a naturally occurring sugar  
**Infection risk** | Minimal with sterile technique (<1:10,000)  
**Contraindications** | Active infection, bleeding disorder, pregnancy, local malignancy  
**Cost** | $200-800 per session (often not covered by insurance)  
  
* * *

## Sources

1. Sarbetter R et al. (2016). "Prolotherapy in Knee Osteoarthritis." PMID 28334196 (PubMed 28334196)
2. Hauser RA et al. (2022). "Prolotherapy: A Narrative Review of Mechanisms." PMID 36410881 (PubMed 36410881)
3. Rabago D et al. (2025). "Prolotherapy as Regenerative Treatment." PMC12472176 (PMC12472176)